Fresenius SE & Co KGaA


Latest Trade






Today's Range




52 Week Range




As of on the XETRA ∙ Minimum 15 minute delay


Previous Close
3M AVG Volume
Today's High
Today's Low
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Forward P/E
Dividend (Yield %)

Next Event

Fresenius SE & Co KGaA at Kepler Cheuvreux & UniCredit German Corporate Conference

Latest Developments


Fresenius Places Bonds With A Volume Of 750 Million Euros

Fresenius Helios Buys Private Hospital in Colombia

Fresenius Kabi Announces Availability In U.S. Of Fosaprepitant For Injection 150 Mg Per Vial


About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.


Healthcare Facilities

Contact Info

Else-Kroener-Str. 1


Executive Leadership

Gerd Krick

Independent Chairman of the Supervisory Board

Stephan Sturm

Chairman of the Management Board, Chief Executive Officer

Michael Diekmann

Independent Deputy Chairman of the Supervisory Board

Niko Stumpfoegger

Independent Deputy Chairman of the Supervisory Board

Dieter Schenk

Deputy Chairman of the Supervisory Board and Lawyer and Tax Consultant

Key Stats

2.12 mean rating - 25 analysts
Revenue (MM, EUR)
















Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)

Latest News

Latest News

Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments

German healthcare group Fresenius <FREG.DE> beat third-quarter revenue forecasts on Tuesday, citing a solid performance by its infusion drugs unit in emerging markets and strong growth in home treatment at its separately listed dialysis business.

Fresenius reports Q3 beat thanks to Kabi growth in emerging markets

German healthcare group Fresenius beat third-quarter revenue forecasts on Tuesday as softer revenue growth in North America was offset by growth of its infusions drugs unit Kabi in emerging markets.

Fresenius drops possible sale of blood transfusion unit - spokesman

German health care group Fresenius <FREG.DE> has abandoned plans to sell its blood transfusion business, a spokesman said on Sunday, confirming a German media report.

Fresenius' Helios division acquires two hospitals in Colombia

German healthcare group Fresenius <FREG.DE> said on Tuesday its hospitals division Helios had acquired two hospitals in Colombia for 50 million euros ($55.72 million) as the group strengthens its presence outside of Europe.

Fresenius slides as weakness in dialysis unit offsets improved outlook

Shares in German healthcare group Fresenius <FREG.DE> slid on Tuesday after its dialysis unit FMC reported smaller than expected cost savings and said full-year earnings growth would likely come in at the lower end of guidance.

Fresenius raises full-year outlook after Q2 meets expectations

German healthcare group Fresenius raised full-year revenue targets on Tuesday as its adjusted second-quarter sales came in a touch above analysts' expectations.

Fresenius says tighter EU rules could trigger antibiotic shortage

German drugmaker Fresenius warned that stricter production norms being considered by Europe's drug regulator could compound shortages of a life-saving antibiotic that is used by about 25 million patients globally each year.

Fresenius CEO: Don't see us making any large acquisitions this year

German healthcare group Fresenius probably will not make any large acquisitions this year, the group's chief executive officer said on Friday, adding that this was more likely from next year.

Fresenius talking to potential suitors about sale of blood transfusion business - sources

Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday.

Fresenius talking to potential suitors about sale of blood transfusion business - sources

Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday.

Fresenius makes solid start to year after turbulent 2018

Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation.

Fresenius makes solid start to Q1 after troubled 2018

Fresenius reported a quarter of solid sales and earnings growth on Thursday helped by its generic infusion drugs and dialysis units and signs of stabilisation at its troubled German hospital business.

Fresenius may not be ideal owner for some business activities: CEO

German healthcare group Fresenius is happy with its current portfolio but may consider selling some non-core business activities within its units, its chief executive told an association of business journalists on Wednesday evening.

Fresenius flags faster earnings growth from 2020 after investment

Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday.

Fresenius expects earnings to stagnate in 2019 as investments weigh

German healthcare group Fresenius said sales growth would slow and profit stagnate this year as investments to fix the performance at its German hospitals business and build up home dialysis take a toll.

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

Akorn Inc <AKRX.O> said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE <FREG.DE>.

UPDATE 2-Fresenius plunges as health firm warns investment to hit profit

* Shares plunge 18 percent, poised for biggest one-day drop (Adds analyst comment, loss in market value)

Fresenius cuts guidance, vows further dividend hikes

German healthcare group Fresenius cut its medium-term guidance late on Thursday hurt by lower profit expectations at its dialysis arm FMC and its clinics chain Helios but said that dividends will continue to grow.

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest...

Fresenius says working to fix performance at dialysis business, German hospitals

Germany's Fresenius <FREG.DE> said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.